


**Product Name** : MRI-1891  
**Cat. No.** : PC-20170  
**CAS No.** : 2712480-46-9  
**Molecular Formula** : C<sub>26</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>3</sub>S  
**Molecular Weight** : 591.01  
**Target** : Cannabinoid Receptor  
**Solubility** : 10 mM in DMSO



## Biological Activity

MRI-1891 (Monlunabant, INV-202) is potent, selective,  $\beta$ -Arrestin-2-biased peripheral **cannabinoid-1 receptor (CB1R)** antagonist with  $K_i$  of 0.3 nM (hCB1R), >2000-fold CB1R/CB2R selectivity.

MRI-1891 displays high bias toward inhibiting CB1R-agonist-induced  $\beta$ -arrestin-2 ( $\beta$ Arr2) recruitment ( $IC_{50}$ =21 pM) versus inhibiting CB1R-agonist-induced G protein activation, as monitored by GTP $\gamma$ S binding ( $IC_{50}$ =6 nM).

In C2C12 myoblasts, CB1R activation suppresses insulin-induced akt-2 phosphorylation, preventable by MRI-1891

MRI-1891 improves obesity-induced muscle insulin resistance in wild-type but not in  $\beta$ Arr2-KO mice.

MRI-1891 augments glucose stimulated insulin secretion in isolated human pancreatic islets and mouse islets, shows comparable insulin secretion enhancing effect to exendin-4.

MRI-1891 treatment protects isolated human islet cells against cytokine-induced apoptosis, similar to exendin-4.

## References

Ziyi Liu, et al. *ACS Pharmacol Transl Sci.* 2021 Apr 8;4(3):1175-1187.

Ghosh A, et al. *Eur J Pharmacol.* 2023 Apr 5;944:175589.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com